ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
01 Sep 2025 10:50

Hong Kong Connect Flows (August): $18bn Inflows

We estimate inflows into HK via southbound trade were $18bn in August, at four month high. We highlight inflows for Alibaba, Tencent, Meituan, and...

Logo
332 Views
Share
01 Sep 2025 03:08

HONG KONG ALPHA PORTFOLIO (August 2025)

Hong Kong Alpha portfolio gained 11.34% in October outperforming its benchmark and HK indexes.  The portfolio's Sharpe ratio increased to 2.91 and...

Logo
460 Views
Share
31 Aug 2025 10:05

HK Connect Flows Weekly (Aug 29th): Meituan, Alibaba, Tencent, AIA, Pop Mart Intl, Kuaishou, SMIC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Meituan, Alibaba, Tencent, AIA, Pop Mart Intl, Kuaishou,...

Logo
418 Views
Share
29 Aug 2025 14:30

Hong Kong Buybacks Weekly (Aug 29th): Tencent, China Hongqiao, Sinopec

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
447 Views
Share
bullishXtalPi Holdings
28 Aug 2025 19:06

Xtalpi Placement: Opportunistic Raise but Thematically Hot, past Deals Did Well

Xtalpi is looking to raise up to US$300m in a primary placement. In this note, we will talk about the placement and run the deal through our ECM...

Logo
471 Views
Share
x